While there remains further work to elucidate mechanistic underpinnings of ETV4 and ETV5 in this context and to fully define the kinase inhibition landscape of LY2874455, our study identifies molecular targets in SCLC relapse biology and nominates a therapeutic candidate that could contribute to increased survival for patients with this aggressive malignancy. This evidence concerns the gene ETV5 and small cell lung carcinoma.